Full Name
Christie Ballantyne, MD
Job Title
Professor Medicine
Organization Name
Baylor College of Medicine
Speaker Bio
Christie M. Ballantyne, MD, is an internationally renowned expert on lipids, atherosclerosis and heart disease prevention. He is the Chief of Cardiovascular Research and the Director of Cardiometabolic Disease Prevention at Baylor College of Medicine.
Dr. Ballantyne's research in the prevention of heart disease led him to become an established investigator for the American Heart Association. Since 1988, Dr. Ballantyne has received continuous funding from the National Institutes of Health to support his basic research of leukocyte-endothelial interactions, translational biomarkers and clinical trials. Clarivate Web of Science named Dr. Ballantyne as a “Highly Cited Researcher” from 2017 to 2022, being in the top 1% of the most-cited investigators. This distinction is based on his 800-plus journal publications in the areas of atherosclerosis, lipids and inflammation. His research has led to the U.S. Food and Drug Administration's approval of 2 biomarkers for cardiovascular risk prediction, and he has played a prominent role in the development and approval of new lipid-lowering therapies.
Dr. Ballantyne's many professional accomplishments include being elected Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. He is the President of the National Lipid Association (NLA), and serves on the Editorial Board of Circulation and the Journal of the American College of Cardiology. In 2012 he received the Distinguished Scientist Award from the American College of Cardiology.
Dr. Ballantyne's research in the prevention of heart disease led him to become an established investigator for the American Heart Association. Since 1988, Dr. Ballantyne has received continuous funding from the National Institutes of Health to support his basic research of leukocyte-endothelial interactions, translational biomarkers and clinical trials. Clarivate Web of Science named Dr. Ballantyne as a “Highly Cited Researcher” from 2017 to 2022, being in the top 1% of the most-cited investigators. This distinction is based on his 800-plus journal publications in the areas of atherosclerosis, lipids and inflammation. His research has led to the U.S. Food and Drug Administration's approval of 2 biomarkers for cardiovascular risk prediction, and he has played a prominent role in the development and approval of new lipid-lowering therapies.
Dr. Ballantyne's many professional accomplishments include being elected Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. He is the President of the National Lipid Association (NLA), and serves on the Editorial Board of Circulation and the Journal of the American College of Cardiology. In 2012 he received the Distinguished Scientist Award from the American College of Cardiology.
Speaking At
